Patient characteristics
| Characteristic . | UM (n = 111) . | P . | FHCRC (n = 178) . | P . | ||
|---|---|---|---|---|---|---|
| GI-cGVHD (n = 23) . | No GI-cGVHD (n = 88) . | GI-cGVHD (n = 63) . | No GI-cGVHD (n = 115) . | |||
| Incidence, % | 21 | 35 | ||||
| Median age, y (range) | 52 (7-66) | 52 (5-68) | .7 | 55 (24-71) | 51 (19-79) | .15 |
| Donor | .64 | .87 | ||||
| Matched unrelated | 11 (48) | 48 (55) | 38 (60) | 67 (58) | ||
| Matched related | 12 (52) | 40 (45) | 25 (45) | 48 (42) | ||
| Cell source | .35 | .06 | ||||
| Peripheral blood stem cells | 21 (91) | 72 (82) | 53 (84) | 108 (94) | ||
| Bone marrow or cord blood | 2 (9) | 16 (18) | 10 (16) | 7 (6) | ||
| Conditioning | 1 | .16 | ||||
| Full intensity | 17 (74) | 64 (73) | 25 (40) | 59 (51) | ||
| Reduced intensity | 6 (26) | 24 (27) | 38 (60) | 56 (49) | ||
| aGVHD | 1 | 1 | ||||
| Previous | 15 (65) | 58 (66) | 48 (76) | 86 (75) | ||
| No previous | 8 (35) | 30 (34) | 15 (24) | 29 (25) | ||
| cGVHD | .3 | .74 | ||||
| Progressive | 8 (35) | 21 (24) | 26 (38) | 39 (34) | ||
| Not progressive | 15 (65) | 67 (76) | 37 (62) | 81 (46) | ||
| Median time from HCT to cGVHD diagnosis, d (range) | 188 (125-485) | 175 (77-547) | .28 | 204 (38-1757) | 216 (82-8876) | .97 |
| Median time from HCT to sample collection, d (range) | 192 (101-547) | 175 (77-384) | .08 | 385 (96-1852) | 395 (91-8973) | .78 |
| NIH score at sample | .46 | .09 | ||||
| 1 | 4 (17) | 25 (28) | 6 (10) | 25 (21) | ||
| 2 | 10 (44) | 38 (44) | 41 (65) | 57 (50) | ||
| 3 | 9 (39) | 25 (28) | 16 (25) | 33 (29) | ||
| GI score at sample | ||||||
| 1 | 20 (87) | NA | 50 (79) | NA | ||
| 2 | 3 (13) | NA | 13 (21) | NA | ||
| 3 | 0 (0) | NA | 0 (0) | NA | ||
| Maximum NIH score | .49 | .40 | ||||
| 1 | 1 (4) | 11 (12) | 3 (5) | 12 (10) | ||
| 2 | 7 (30) | 28 (32) | 31 (49) | 56 (49) | ||
| 3 | 15 (65) | 49 (56) | 29 (46) | 47 (41) | ||
| Maximum GI score | ||||||
| 1 | 18 (78) | NA | 44 (70) | NA | ||
| 2 | 5 (22) | NA | 18 (29) | NA | ||
| 3 | 0 (0) | NA | 1 (1) | NA | ||
| Maximum GI score for additional patients who developed new GI-cGVHD | +13 | +26 | ||||
| 1 | 8 (62) | 23 (89) | ||||
| 2 | 3 (23) | 0 (0) | ||||
| 3 | 2 (15) | 3 (11) | ||||
| Characteristic . | UM (n = 111) . | P . | FHCRC (n = 178) . | P . | ||
|---|---|---|---|---|---|---|
| GI-cGVHD (n = 23) . | No GI-cGVHD (n = 88) . | GI-cGVHD (n = 63) . | No GI-cGVHD (n = 115) . | |||
| Incidence, % | 21 | 35 | ||||
| Median age, y (range) | 52 (7-66) | 52 (5-68) | .7 | 55 (24-71) | 51 (19-79) | .15 |
| Donor | .64 | .87 | ||||
| Matched unrelated | 11 (48) | 48 (55) | 38 (60) | 67 (58) | ||
| Matched related | 12 (52) | 40 (45) | 25 (45) | 48 (42) | ||
| Cell source | .35 | .06 | ||||
| Peripheral blood stem cells | 21 (91) | 72 (82) | 53 (84) | 108 (94) | ||
| Bone marrow or cord blood | 2 (9) | 16 (18) | 10 (16) | 7 (6) | ||
| Conditioning | 1 | .16 | ||||
| Full intensity | 17 (74) | 64 (73) | 25 (40) | 59 (51) | ||
| Reduced intensity | 6 (26) | 24 (27) | 38 (60) | 56 (49) | ||
| aGVHD | 1 | 1 | ||||
| Previous | 15 (65) | 58 (66) | 48 (76) | 86 (75) | ||
| No previous | 8 (35) | 30 (34) | 15 (24) | 29 (25) | ||
| cGVHD | .3 | .74 | ||||
| Progressive | 8 (35) | 21 (24) | 26 (38) | 39 (34) | ||
| Not progressive | 15 (65) | 67 (76) | 37 (62) | 81 (46) | ||
| Median time from HCT to cGVHD diagnosis, d (range) | 188 (125-485) | 175 (77-547) | .28 | 204 (38-1757) | 216 (82-8876) | .97 |
| Median time from HCT to sample collection, d (range) | 192 (101-547) | 175 (77-384) | .08 | 385 (96-1852) | 395 (91-8973) | .78 |
| NIH score at sample | .46 | .09 | ||||
| 1 | 4 (17) | 25 (28) | 6 (10) | 25 (21) | ||
| 2 | 10 (44) | 38 (44) | 41 (65) | 57 (50) | ||
| 3 | 9 (39) | 25 (28) | 16 (25) | 33 (29) | ||
| GI score at sample | ||||||
| 1 | 20 (87) | NA | 50 (79) | NA | ||
| 2 | 3 (13) | NA | 13 (21) | NA | ||
| 3 | 0 (0) | NA | 0 (0) | NA | ||
| Maximum NIH score | .49 | .40 | ||||
| 1 | 1 (4) | 11 (12) | 3 (5) | 12 (10) | ||
| 2 | 7 (30) | 28 (32) | 31 (49) | 56 (49) | ||
| 3 | 15 (65) | 49 (56) | 29 (46) | 47 (41) | ||
| Maximum GI score | ||||||
| 1 | 18 (78) | NA | 44 (70) | NA | ||
| 2 | 5 (22) | NA | 18 (29) | NA | ||
| 3 | 0 (0) | NA | 1 (1) | NA | ||
| Maximum GI score for additional patients who developed new GI-cGVHD | +13 | +26 | ||||
| 1 | 8 (62) | 23 (89) | ||||
| 2 | 3 (23) | 0 (0) | ||||
| 3 | 2 (15) | 3 (11) | ||||
All data represent No. (%) unless otherwise designated.
NA, not applicable.
Indicates patients that did not have GI-cGVHD at time of sample collection but went on to later develop GI-cGVHD.